FDA Faces Law Suit Over Sudden Removal of Tirzepatide from Drug Shortage List
Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.
Milvexian, FXIa Inhibitor, Wins US FDA Fast Track Designation for 3 Indications in Phase 3 Trial Program
Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
